Smith & Wesson Brands Earnings Calls
| Release date | Dec 04, 2025 |
| EPS estimate | $0.0200 |
| EPS actual | - |
| Revenue estimate | 123.729M |
| Revenue actual | - |
| Expected change | +/- 4.35% |
| Release date | Sep 04, 2025 |
| EPS estimate | $0.0200 |
| EPS actual | -$0.0800 |
| EPS Surprise | -500.00% |
| Revenue estimate | 121.246M |
| Revenue actual | 85.077M |
| Revenue Surprise | -29.83% |
| Release date | Jun 18, 2025 |
| EPS estimate | $0.230 |
| EPS actual | $0.200 |
| EPS Surprise | -13.04% |
| Revenue estimate | 152.405M |
| Revenue actual | 140.762M |
| Revenue Surprise | -7.64% |
| Release date | Mar 06, 2025 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0200 |
| Revenue estimate | 152.405M |
| Revenue actual | 115.885M |
| Revenue Surprise | -23.96% |
Last 4 Quarters for Smith & Wesson Brands
Below you can see how SWBI performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Mar 06, 2025 |
| Price on release | $11.02 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0200 |
| Date | Price |
|---|---|
| Feb 28, 2025 | $10.86 |
| Mar 03, 2025 | $10.75 |
| Mar 04, 2025 | $10.75 |
| Mar 05, 2025 | $10.80 |
| Mar 06, 2025 | $11.02 |
| Mar 07, 2025 | $9.82 |
| Mar 10, 2025 | $9.40 |
| Mar 11, 2025 | $9.61 |
| Mar 12, 2025 | $9.77 |
| 4 days before | 1.47% |
| 4 days after | -11.34% |
| On release day | -10.93% |
| Change in period | -10.04% |
| Release date | Jun 18, 2025 |
| Price on release | $10.88 |
| EPS estimate | $0.230 |
| EPS actual | $0.200 |
| EPS surprise | -13.04% |
| Date | Price |
|---|---|
| Jun 12, 2025 | $10.69 |
| Jun 13, 2025 | $10.51 |
| Jun 16, 2025 | $10.69 |
| Jun 17, 2025 | $10.49 |
| Jun 18, 2025 | $10.88 |
| Jun 20, 2025 | $8.73 |
| Jun 23, 2025 | $8.69 |
| Jun 24, 2025 | $8.60 |
| Jun 25, 2025 | $8.59 |
| 4 days before | 1.78% |
| 4 days after | -21.05% |
| On release day | -19.81% |
| Change in period | -19.64% |
| Release date | Sep 04, 2025 |
| Price on release | $8.21 |
| EPS estimate | $0.0200 |
| EPS actual | -$0.0800 |
| EPS surprise | -500.00% |
| Date | Price |
|---|---|
| Aug 28, 2025 | $8.07 |
| Aug 29, 2025 | $8.17 |
| Sep 02, 2025 | $8.13 |
| Sep 03, 2025 | $8.02 |
| Sep 04, 2025 | $8.21 |
| Sep 05, 2025 | $8.74 |
| Sep 08, 2025 | $8.84 |
| Sep 09, 2025 | $8.80 |
| Sep 10, 2025 | $9.39 |
| 4 days before | 1.73% |
| 4 days after | 14.37% |
| On release day | 6.46% |
| Change in period | 16.36% |
| Release date | Dec 04, 2025 |
| Price on release | - |
| EPS estimate | $0.0200 |
| EPS actual | - |
| Date | Price |
|---|---|
| Nov 11, 2025 | $8.65 |
| Nov 12, 2025 | $8.66 |
| Nov 13, 2025 | $8.54 |
| Nov 14, 2025 | $8.47 |
| Nov 17, 2025 | $8.30 |
Smith & Wesson Brands Earnings Call Transcript Summary of Q3 2025
Key points for investors: Revenues softened — Q3 net sales were $115.9M, down 15.7% year-over-year — driven by weak demand for legacy/core products and lower ASPs driven by mix. New products remain a growth engine: items introduced in the past year accounted for over 41% of Q3 sales (Bodyguard 2.0 is a standout), and management says two-year long-gun unit sales grew at a ~20% CAGR. Profitability held up versus guidance through cost control and flexible manufacturing, but gross margin compressed to 24.1% (down ~4.6 percentage points) due to lower production absorption and higher promotions. Q3 GAAP net income was $1.7M ($0.04 EPS); non-GAAP EPS was $0.02. Cash used in operations was $9.8M in the quarter; the company ended Q3 with $26.7M cash and $110M drawn on its credit line, with a $10M repayment made post-quarter and plans for further paydown. Capital allocation remains shareholder-friendly: a $0.13 quarterly dividend, continued share repurchases (220k shares in Q3; >1.5M net reduction YTD), and targeted capex of $20–25M for fiscal year. Guidance and outlook: management still expects full-year revenue down 5–10% vs. FY24 but now expects results near the lower end (close to a 10% decline); Q4 revenue expected down ~2–5% and margins likely to be a few percentage points lower as production absorption is reduced. Channel inventory is healthy (~<9 weeks) though internal inventory is slightly elevated; management emphasizes continued investment in innovation, disciplined expense control, flexible manufacturing, and debt reduction to sustain cash flow and shareholder returns.
Sign In
Buy SWBI